Introduction
Adrenomedullin (AM) and calcitonin gene-related peptide (CGRP) belong to a family of structurally related peptides which also includes calcitonin (CT) and amylin (for review see refs. 2 and 3). AM is recognized in several cell types and tissues. CGRP is predominantly synthesized in the central and peripheral nervous system. AM and CGRP have in common a six amino acid ring structure formed by disulfide bridges near the N-terminus, and amidated C-termini, both of which are required for biological activity. The ring structures are not essential for receptor binding. The N-truncated CGRP , human (h) AM and rat (r) AM fragments lacking the ring structures are competitive antagonists. Specific binding sites for AM and CGRP are widely distributed. Both AM and CGRP are potent vasodilators.
The structure of AM and CGRP receptors remained elusive until the discovery of a new principle of associated receptor-activity-modifying proteins (RAMP) required for the Here, we have summarized the AM and CGRP pharmacology of hCL, rCL, pCL and bCL receptors interacting with RAMP2 and RAMP3. The findings are compared to the properties of AM receptors in tissues and cell lines. Importantly, the majority of the studies with cloned CL receptors have made use of human embryonal kidney HEK293 cell lines where endogenous RAMP may form functional CGRP and AM receptors with transiently and stably transfected CL receptors alone (8, 9, 13) . Monkey kidney COS7 cells, on the other hand, which do not reveal recognizable receptors and RAMP, are suitable for the analysis of the functional expression of the receptors (14, 15) .
The CL Receptor/RAMP2 Defines the AM1 Receptor
Co-expression of the hCL receptor with hRAMP2 in HEK293 cells results in [ 125 I]AM binding that is inhibited by AM with an IC50 of between 0.8 and 9.7 nmol/l, and the antagonist hAM(22-52) was 23-fold less potent (Table 1) . CGRP , αCGRP and βCGRP were at least two orders of magnitude less potent than AM with a rank order of CGRP(8-37) βCGRP αCGRP. Amylin and CT were inactive.
When the rCL receptor was co-transfected with hRAMP2 or mRAMP2 in COS7, osteoblast-like UMR-106 or Drosophila Schneider 2 (S2) cells, the IC50 of AM ranged from 0.4 to 1.9 nmol/l, and rAM(20-50) was 7-fold less potent. CGRP, amylin and CT were largely inactive as with the hCL receptor. When the rCL receptor and rRAMP2 were expressed in UMR-106 cells, the antagonists rAM(20-50) and CGRP were one to two orders of magnitude less potent than with hRAMP2 or mRAMP2.
When the bCL receptor was co-transfected with hRAMP2 in HEK293 cells, hAM and αCGRP inhibited [
125 I]AM binding with a 68-and 1,000-fold lower potency than AM. But here CGRP(8-37) was inactive. In another study using co-transfection of the pCL receptor with hRAMP2 in HEK293 cells, the IC50 of AM was 3 nmol/l, and hAM(22-52) was 24-fold less potent, much like with the hCL receptor/hRAMP2 complex. But here, α-and βCGRP were only 11 and 20 times less potent than AM. It remains to be shown whether this apparent reduced selectivity is due to species differences.
Taken together, these results indicate that the rank order of [ 125 I]AM binding inhibition of the hAM1, rAM1, and bAM1 receptor was AM AM antagonist CGRP(8-37) ≥βCGRP≥αCGRP amylin CT.
In HEK293 cells co-transfected with hCL, pCL, or bCL receptor and hRAMP2, AM stimulated cAMP formation with an EC50 of between 0.5 and 5 nmol/l ( Table 2) . α-and βCGRP were 5-150-fold (mean value 70-fold) less potent than AM.
Transfection of the rCL receptor in UMR-106 cells expressing endogenous rRAMP2, but not rRAMP1, and cotransfection of rCL receptor with hRAMP2, rRAMP2, or mRAMP2 in HEK293, COS7 and S2 cells resulted in an EC50 of cAMP formation of AM of between 0.2 and 8 nmol/l. α-and βCGRP, amylin and CT were 2 to 3 orders of magnitude less potent than AM. This contrasts with the lower selectivity of the hCL and pCL receptors co-transfected with RAMP2 in HEK293 cells. Some cell lines express RAMP1, and the hCL and pCL receptor have been shown to be expressed as CGRP receptors in the absence of cotransfected RAMP1 (8, 13) . In other cell lines there is evidence for the expression of RAMP2 (9, 16) . In addition to endogenous RAMP, some HEK293 cells also express CT receptors with which RAMP1 and -3 interact (17) (18) (19) (14) . It remains to be investigated in more detail whether the reduced selectivity of AM over CGRP observed in some studies in HEK293 cells with the CL receptors is due to mixed CT receptor/RAMP and CL receptor/RAMP. Pharmacological characterization of CL receptors/RAMP should therefore be established if possible with a cellular background without recognizable RAMP, CT or CL receptors, e.g. in COS7 cells. The rank order of potency of the agonists observed in COS7 cells, AM CGRP≥ amylin CT, is consistent with the profile observed in AM-binding inhibition, and therefore corresponds to the AM1 receptor obtained by co-expression of a CL receptor with RAMP2. Three hundred nanomoles per liter hAM(22-52), unlike 100 nmol/l CGRP(8-37), antagonized AM-stimulated cAMP accumulation in HEK293 cells co-transfected with hCL or pCL receptors and hRAMP2 (20; N. Aiyar, personal communication). A Ki of 25 nmol/l hAM(22-52) was calculated for both receptors. When bCL receptors were co-transfected with hRAMP2, hAM(22-52) was 20-fold more potent then CGRP(8-37) (9). These results are in accordance with the 10-100-fold higher potency of hAM(22-52) over CGRP in AM-binding inhibition. The AM response was also antagonized by hAM(22-52), but not by CGRP , in yeast cells transfected with a pCL receptor and pRAMP2 (21) . For the rCL receptor/RAMP2, no Ki values are available, although antagonism of rAM (20-50) is predicted based on the observed IC50.
Taken together, these results indicate that the CL receptor/RAMP2 AM1 receptor selectively recognizes AM, unlike CGRP, amylin and CT, and this receptor is antagonized by hAM(22-52) but not by CGRP(8-37).
The CL Receptor/RAMP3 Defines the AM2 Receptor (Table 3) . Binding inhibition was more potent with AM than with CGRP, but the discrimination between AM and CGRP was less evident than with the AM1 receptor. When the hCL receptor was co-transfected with hRAMP3, α-and βCGRP, Muff et (15) . The expressed mRAMP3, moreover, reduced the mRAMP2-induced [
125 I]AM binding. The AM2 receptor, therefore, differs from the AM1 receptor in that the former has a lower selectivity for AM in relation to CGRP. The AM2 receptor is considered an AM preferring receptor. Species differences cannot be excluded, since with the bovine CL receptor, both AM1 and AM2 receptors are selective for AM.
Cyclic AMP accumulation has been studied in HEK293 cells co-expressing either hCL receptor/hRAMP3, rCL receptor/rRAMP3, pCL receptor/hRAMP3 or bCL receptor/hRAMP3 with an EC50 of AM ranging from 0.2 to 5 nmol/l (mean value 3 nmol/l) ( Table 4) . α-and βCGRP were 9-200-fold (mean value 65-fold) less potent than AM. In COS7 cells co-transfected with the rCL receptor and mRAMP3, the α-and βCGRP were 10 times less potent, and amylin and CT 200-fold less potent than AM. Here, the selectivity of AM over CGRP was reduced by one order of magnitude compared to the AM1 receptor. Together, these results indicate that the AM2 receptor is less selective for AM in relation to CGRP also with respect to the stimulation of cAMP formation.
In HEK293 cells transfected with hCL or pCL receptor together with hRAMP3, AM-stimulated cAMP accumulation was antagonized by 300 nmol/l hAM (22- antagonized AM-stimulated cAMP formation with a Ki of 330 nmol/l, and hAM(22-52) was inactive (22) . Species differences in the recognition of CGRP(8-37) cannot be excluded. Taken together, these results indicate that the AM2 receptor differs from the AM1 receptor by its recognition of CGRP. In humans, pigs and cows, it cannot be distinguished from the AM1 receptor by the use of the hAM(22-52) and CGRP antagonists. 
AM Receptors in Tissues and Cells
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into this cellular background enabled also CGRP to stimulate cAMP in the subnanomolar range, and this response was then antagonized by CGRP(8-37) with a Ki of 3 nmol/l but not by hAM . The antagonists hAM and CGRP can therefore distinguish AM from co-expressed CGRP receptors. Taken together, these results provide evidence for a selective AM1 receptor that recognizes AM but not CT, CGRP or amylin, all of which belong to the CT family of peptides. The receptors are selectively antagonized by N-truncated hAM(22-52).
There is evidence for similar potencies of AM and CGRP in various types of cells, such as guinea pig smooth muscle cells or rat thoracic aorta cells (26, 27) . In both of these cell types, AM was 2-3-fold more potent than CGRP. It remains to be shown whether this is due to the expression of an AM2 receptor or due to co-expression of a CGRP receptor with an AM1 receptor. An AM receptor was discovered in rat astrocytes, where αCGRP and amylin also displaced [ 125 I]AM binding, although at 80-fold lower potency, and CT was inactive (24) . Interestingly, CGRP(8-37) was only 9 times less potent than AM, whereas hAM(22-52) was 200-fold less potent. αCGRP and amylin were 200-fold less active than AM in the stimulation of cAMP formation, and CT was inactive. In accordance with the binding inhibition of [ 125 I]AM by CGRP , the peptide inhibited AM-stimulated cAMP accumulation with a Ki of 92 nmol/l, and was four times more potent than hAM . A similar receptor may exist in Swiss 3T3 mouse fibroblasts, in which CGRP(8-37) and hAM were equipotent antagonists with a Ki of 130 nmol/l (28). In certain tissues, the AM response is antagonized by CGRP(8-37) and not by hAM(22-52) (21, (28) (29) (30) (31) . In these tissues, AM presumably interacts with the CGRP1 receptor defined as the CL receptor associated with RAMP1. But CGRP was 20-100-fold more potent than AM as in SK-N-MC neuroblastoma cells which express the CL receptor and RAMP1 proteins (32) (33) (34) (35) . In these cells, the Ki of CGRP(8-37) with respect to inhibition of CGRP and AM-stimulated cAMP accumulation was the same. This indicates that both peptides interact with a single CGRP1 receptor. An AM response antagonized by CGRP(8-37) does not, therefore, implicate another AM receptor subtype. Obviously, endogenous and therefore non-transfected receptors should be related to the levels of mRNA encoding CL receptor and RAMP1, -2 and -3 and the expressed proteins in tissues and cells. However, some discrepancies are apparent, such as cases in which CL receptor mRNA is undetectable by Northern blot analysis, but identifiable CL receptor proteins are apparent, as in L6-1 myoblasts that specifically bind [
125 I]AM (34). In conclusion, an AM selective AM1 and an AM preferring AM2 receptor are composed of the CL receptor co-expressed with RAMP2 and -3, respectively (1). The AM1 receptor which does not recognize CGRP and CGRP to any great extent, and is antagonized by truncated hAM(22-52) rather than CGRP , may be expressed in NG108-15 cells, as well as in other cell types. The AM2 receptor, antagonized by hAM or CGRP(8-37), recognizes CGRP together with AM, and is defined as the CL/RAMP3 receptor. An AM receptor that prefers CGRP(8-37) over hAM may be expressed in such cells as rat astrocytes, where the AM response is antagonized by CGRP . Nonetheless, it remains to be confirmed that the mixed AM/CGRP receptor is a CL receptor/RAMP3 complex.
